Zentiva
Zentiva, a leading pharmaceutical company headquartered in the Czech Republic (CZ), has established itself as a key player in the generic and specialty medicines sector since its founding in 2003. With a strong presence across Europe, Zentiva focuses on delivering high-quality, affordable healthcare solutions that cater to diverse patient needs. The company’s core offerings include a wide range of generic medications, over-the-counter products, and specialty pharmaceuticals, all designed to enhance patient access to essential treatments. Zentiva is recognised for its commitment to quality and innovation, ensuring that its products meet rigorous industry standards. Notable achievements include expanding its operational footprint in major European markets, positioning Zentiva as a trusted partner in healthcare. With a dedication to sustainability and patient-centric solutions, Zentiva continues to make significant strides in the pharmaceutical industry.
DitchCarbon Score
How does Zentiva's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Zentiva's score of 83 is higher than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Zentiva's reported carbon emissions
In 2024, Zentiva reported total carbon emissions of approximately 411,860,000 kg CO2e. This figure includes 13,722,000 kg CO2e from Scope 1 emissions, 14,088,000 kg CO2e from Scope 2 (market-based), and a significant 384,050,000 kg CO2e from Scope 3 emissions. The Scope 3 emissions are primarily driven by purchased goods and services, which account for about 308,083,000 kg CO2e. Zentiva has set ambitious climate commitments, aiming to achieve carbon neutrality in both Scope 1 and Scope 2 emissions by 2030. This commitment reflects a proactive approach to reducing their carbon footprint and aligns with industry standards for sustainability. The company is currently in the early stages of this initiative, having started in 2023. In comparison, the previous year's emissions in 2023 were reported at approximately 81,444,000 kg CO2e, with Scope 1 emissions at 15,038,000 kg CO2e and Scope 2 emissions (market-based) at 13,607,000 kg CO2e. This indicates a significant increase in total emissions in 2024, highlighting the challenges faced in emission reduction efforts. Zentiva's ongoing commitment to sustainability and carbon reduction is crucial in the pharmaceutical industry, where environmental impact is increasingly scrutinised. The company's focus on reducing Scope 1 and 2 emissions by 2030 demonstrates a clear strategy towards achieving a more sustainable operational model.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Scope 1 | 31,972,200 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 15,963,700 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 55,656,900 | 00,000,000 | 00,000,000 | 00,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Zentiva is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
